Small study checks how liver disease affects new drug processing

NCT ID NCT04676425

Completed Knowledge-focused Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested a single 4 mg dose of the drug elpipodect (MK-8189) in 14 people—some with mild or moderate liver problems and some healthy. Researchers measured how much drug stayed in the blood and for how long. The goal was to see if liver impairment changes drug levels, which could guide future dosing. No treatment benefit was tested.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Elpipodect (MK-8189)
What this could lead to: If successful, this study could help doctors decide the right dose of MK-8189 for patients with liver problems.
What could go wrong: This is a very early, small study with only 14 participants. It only looks at how the drug moves through the body, not whether it works for any disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATIC IMPAIRMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

liver disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATIC IMPAIRMENT

Contacts and locations

Locations

Clinical Pharmacology of Miami ( Site 0001)

Miami, Florida, 33014, United States
ProSciento Inc. ( Site 0002)

Chula Vista, California, 91911, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.